HemaSphere (Jun 2022)

P696: SUBTHERAPEUTIC TKI DOSES FOR THE MAINTENANCE OF CML PATIENTS WITH INTOLERANCE OR REFUSAL TO DISCONTINUE: A SINGLE CENTER FEASIBILITY STUDY.

  • A. Borrero,
  • A. Segura,
  • S. Sanchez,
  • R. Stuckey,
  • J. F. López,
  • C. Bilbao,
  • M. T. Gomez casares

DOI
https://doi.org/10.1097/01.HS9.0000845668.52210.0f
Journal volume & issue
Vol. 6
pp. 591 – 592

Abstract

Read online

No abstracts available.